Status:
UNKNOWN
Total Arterial Revascularization (TAR)
Lead Sponsor:
Meshalkin Research Institute of Pathology of Circulation
Collaborating Sponsors:
Kemerovo Cardiology Center
Conditions:
Coronary Artery Disease
Coronary Artery Bypass Grafting
Eligibility:
All Genders
25-70 years
Phase:
NA
Brief Summary
Total arterial revascularisation with in-situ confihuration of BITA is superior than y-graft in patients underwent CABG.
Detailed Description
The main hypothesis of the trial is that in-situ configuration of bilateral internal thoracic arteries is superior than Y-graft configuration for MACCE (mortality, myocardial infarction, repeat revasc...
Eligibility Criteria
Inclusion
- Coronary Artery Disease
- Stable angina
- The need for revascularization of anterior descending and obtuse margin arteries accoring to the 2018 ESC/EACTS Guidelines on myocardial revascularization
- Informed Consent Form
Exclusion
- The diameter of the target arteries is less than 1 mm
- Stenosis of the subclavian arteries more than 60%
- STEMI less than 3 month
- Previous cardiac surgery
- BMI \>35
- COPD with FEV1 \<60%
- Concomitant pathology that requires simultaneous surgical treatment
- Cancer with life expectancy less than 5 years
Key Trial Info
Start Date :
March 13 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2024
Estimated Enrollment :
880 Patients enrolled
Trial Details
Trial ID
NCT03753048
Start Date
March 13 2018
End Date
March 1 2024
Last Update
December 11 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Meshalkin National Medical Research Center
Novosibirsk, Novosibirsk Oblast, Russia, 630055